Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor class drugs

9 results

  • apretude

    (Cabotegravir)
    ViiV Healthcare Company
    APRETUDE is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk of HIV-1. A negative HIV-1 test is required before starting treatment.

  • cabenuva

    (cabotegravir and rilpivirine)
    ViiV Healthcare Company
    CABENUVA is indicated for the treatment of HIV-1 infection in adults and adolescents (≥12 years, ≥35 kg) as a complete regimen, replacing current antiretroviral therapy in those who are virologically suppressed with no treatment failure history and no known resistance to cabotegravir or rilpivirine.

  • dovato

    (dolutegravir sodium and lamivudine)
    ViiV Healthcare Company
    DOVATO is indicated for the treatment of HIV-1 infection in adults and adolescents (12 years and older, weighing at least 25 kg) who are either treatment-naive or virologically suppressed on a stable regimen without known resistance issues.

  • genvoya

    (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
    Gilead Sciences, Inc.
    GENVOYA is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥25 kg) with no prior antiretroviral treatment history or to replace an existing regimen in virologically-suppressed patients on a stable regimen for at least six months without treatment failures or resistance.

  • isentress

    (RALTEGRAVIR)
    Merck Sharp & Dohme LLC
    ISENTRESS® and ISENTRESS® HD are indicated for the treatment of HIV-1 infection in adults and pediatric patients, used in combination with other antiretroviral agents. ISENTRESS is for children weighing at least 2 kg, while ISENTRESS HD is for those weighing at least 40 kg.

  • juluca

    (dolutegravir sodium and rilpivirine hydrochloride)
    ViiV Healthcare Company
    JULUCA is indicated for treating HIV-1 infection in virologically suppressed adults, replacing their current antiretroviral regimen. Eligible patients must have maintained suppression for at least 6 months, have no treatment failures, and no known resistance to JULUCA's components.

  • stribild

    (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
    Gilead Sciences, Inc.
    STRIBILD® is indicated for treating HIV-1 in adults and pediatric patients aged 12 and older (weighing at least 35 kg) without prior antiretroviral treatment or to replace a stable regimen in those virologically suppressed for at least 6 months, without resistance to its components.

  • tivicay pd

    (dolutegravir sodium)
    ViiV Healthcare Company
    TIVICAY and TIVICAY PD are indicated for treating HIV-1 infection in adults and pediatric patients (aged 4 weeks and older, weighing at least 3 kg) in combination with other antiretrovirals. TIVICAY can also replace a stable regimen in adults who are virologically suppressed.

  • triumeq

    (abacavir sulfate, dolutegravir sodium, lamivudine)
    ViiV Healthcare Company
    TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and pediatric patients aged at least 3 months and weighing at least 6 kg. They are not recommended for patients with integrase resistance or suspected INSTI resistance due to insufficient dolutegravir dosage.